Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Relief Therapeutics Ord Shs RLFTF

Healthcare Biotechnology

RELIEF THERAPEUTICS Holding SA is a Switzerland-based biopharmaceutical company. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. It specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of... see more

Add To Watchlist

Recent & Breaking News (OTCQB:RLFTF)

Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom

ACCESS Newswire January 17, 2023

Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA(TM) for Patients with Urea Cycle Disorders

GlobeNewswire December 27, 2022

Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission

ACCESS Newswire December 27, 2022

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements

ACCESS Newswire December 20, 2022

Relief Therapeutics to Participate in January Investor Meetings

ACCESS Newswire December 14, 2022

Relief Therapeutics Announces Issuance of Shares from Authorized Capital

ACCESS Newswire December 13, 2022

Relief Therapeutics Announces Executive Leadership Team Changes

ACCESS Newswire December 8, 2022

APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival

ACCESS Newswire November 21, 2022

Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission

ACCESS Newswire November 16, 2022

Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. Further Extend their Stay of Pending Litigation to Provide Additional Time for the Parties to Finalize their Litigation Settlement

ACCESS Newswire November 8, 2022

Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)

ACCESS Newswire November 7, 2022

RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. Extend Their Stay of Pending Litigation to Provide Additional Time for The Parties to Finalize Their Settlement

ACCESS Newswire October 26, 2022

Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with the U.S. Securities and Exchange Commission

ACCESS Newswire October 25, 2022

Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer

ACCESS Newswire October 14, 2022

Relief Announces U.S. Launch of PKU GOLIKE

ACCESS Newswire October 10, 2022

Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S.

ACCESS Newswire October 6, 2022

Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit Comprising Phenylbutyrate and Sodium Benzoate

GlobeNewswire October 3, 2022

Relief Reports Half-Year 2022 Results and Provides Corporate Update

ACCESS Newswire September 15, 2022

Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum

ACCESS Newswire September 12, 2022

Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

ACCESS Newswire September 7, 2022